Biomedical Technology, Type 1 Diabetes
Conditions
Keywords
Medtronic 670G
Brief summary
Observational study of patients at Boston Childrens Hospital with type 1 diabetes (T1D) who elected to treat their diabetes with the Medtronic 670 G hybrid closed loop insulin pump.
Detailed description
Outcome study of 90-100 patients with type 1 diabetes who elected to use the Medtronic 670G. Major outcome measure was to assess the percent of patients who were able to successfully continue to use the 670G technology over time. Additional outcome variables included hemoglobin A1c pre and post treatment with the 670G, time in desired glucose range 70-180.
Interventions
DEVICEMedtronic 670G insulin pump
* percent of patients who continue to use Medtronic 670G over time * impact of 670G on glycemic control: hemoglobin A1c, time in range
Sponsors
Boston Children's Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
5 Years to 25 Years
Inclusion criteria
* clinical diagnosis of T1D * patient of Boston Childrens Hospital diabetes program * deemed to be adequate candidates for hybrid closed loop technology by their diabetes health care team * patient received Medtronic 670G training at Boston Childrens Hospital * patient received follow up diabetes care at Boston Childrens Hospital for at least 3 months after starting on the 670G
Exclusion criteria
* patients not trained at Boston Childrens Hospital or self started
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Successful implementation of hybrid closed loop technology | 0-24 months | Percent of Type 1 Diabetes patients who were properly trained on the use of the 670G that continue to use Hybrid Closed Loop technology at 0, 6, 12, 18 and 24 months post training. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Impact of hybrid closed loop technology on glycemic control | 0-24 months | Assess impact of hybrid closed loop technology on glycemic control by comparing hemoglobin A1c measurements 0-6 months prior to treatment versus 0-6, 6-12, 12-18, 18-24 months post treatment |
| Assess impact of hybrid closed loop technology on glycemic control by analysis of sensor glucose data. | 0-24 months. | Compare sensor glucose data: 1) percent time in range (70-180 mg/dl), 2)percent time in auto-mode, 3) percent time sensor usage versus hemoglobin A1c data over time. |
Countries
United States
Outcome results
None listed